Access any target with VeRSa-Select™— for high-quality antibody reagents for GPCRs, ion channels, transporters, and more. The only service that delivers reagent antibodies that cross-react with any mammalian species—including humans, mice, NHPs, and more.
The Leading Platform for Accessing Difficult Targets
Cell Surface Bio leverages the 20+ years of antibody discovery and validation expertise of our parent company, Integral Molecular, whose MPS Antibody Discovery Platform is tailored to deliver therapeutic antibodies against even the most challenging protein targets. Our antibody discovery platform uses only high-quality native immunogens (mRNA and Lipoparticle™ immunizations), and evolutionarily divergent chicken host animals to elicit a robust immune response against any mammalian target (Banik et al., 2023). This high-throughput platform has been used to successfully discover thousands of antibodies.
CSB’s workflows developed for reliable antibody performance are customizable for VeRSa-Select antibodies, with options including:
- Validation in flow cytometry, immunofluorescence, immunohistochemistry, and other key applications
- Rigorous testing for specificity against 6,000+ native proteins using the Membrane Proteome Array™
- Recombinant cloning for animal-free production, batch-to-batch consistency, enhanced detection, and reproducible results
Our mAbs Are Pan-Reactive to Bridge Animal and Human Studies
VeRSa-Select™ delivers mAbs designed for cross-species reactivity, enabling seamless progression from preclinical models to human systems—supporting target
validation and translational research across species.
- Validate Across Species: Assess target relevance in mice, rats, NHPs, and other mammalian models. Isolate mAbs against targets from any mammalian species: mouse, cynomolgus, rhesus, marmoset, rat, rabbit, ferret, pig, bat, guinea pig, and more.
- One mAb for Preclinical Studies: Confirm safety and efficacy in preclinical models and localization in human tissues with the same mAb.
Project Workflow
Contact Us to Get a Quote and Start a Project
Frequently Asked Questions
We immunize chickens—a highly divergent host compared to mammals—using only high quality antigens, a combination of mRNA and Lipoparticles™, to present native protein structures. This approach drives a strong immune response even against conserved mammalian epitopes, enabling us to generate antibodies against challenging targets that other platforms miss.
VeRSaMAbs® are the highest-quality reagent antibodies you can buy. They are extensively validated, recombinantly cloned for batch-to-batch consistency, and profiled for specificity against the entire 6,000 membrane proteome. We provide detailed data on application performance and cross-species reactivity—eliminating the guesswork so you can select the right antibody with confidence.
Pan-reactive antibodies are monoclonal antibodies that bind to orthologs of a target protein across multiple mammalian species—such as humans, mice, rats, and non-human primates. This cross-reactivity enables seamless in vivo and in vitro studies, streamlining target validation and reducing the need for separate species-specific reagents. This means that you can confirm safety and function in preclinical models and, using the same mAb, localize your target in human tissues.
Every VeRSaMAb® antibody in our catalog is recombinantly produced and extensively validated across major applications including flow cytometry, immunofluorescence, immunocytochemistry, and western blot. Specificity is confirmed using the Membrane Proteome Array™ (MPA), which tests binding against 6,000+ native human membrane proteins. Custom reagents are validated using the same process, testing the applications specified by the customer.
Starting a project is easy. Just contact us with your protein of interest—whether it's a well-characterized antigen or a novel membrane target—and we’ll walk you through timelines, options, deliverables, and pricing. No antigen is needed to start your project, just the sequence of your target.